Also see: Juniper, PetSmart: Analysts' New Ratings
Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
STOCK COMMENTS / EPS CHANGES
(AKS - Get Report)
numbers lowered at Goldman. Shares of AKS now seen reaching $12, according to Goldman Sachs. Estimates also cut, as costs continue to rise. Sell rating.
Affiliated Managers Group
(AMG - Get Report)
estimates, target increased at Citigroup. Shares of AMG now seen reaching $125. Estimates also raised on higher EPS and flow visibility. Buy rating.
(AMZN - Get Report)
target raised at Morgan Stanley. Shares of AMZN now seen reaching $275, according to Morgan Stanley. Company continues to see solid sales growth across the board. Overweight rating.
Amazon.com estimates, target adjusted at UBS. Shares of AMZN now seen reaching $215 on accelerating demand, according to UBS. Estimates lowered through 2012. Neutral rating.
(APC - Get Report)
numbers raised at Goldman. Shares of APC now seen reaching $100. Estimates also increased, given a better exploration outlook. Neutral rating.
Anadarko estimates, target raised at Citigroup. Shares of APC now seen reaching $100. Estimates also raised on heightened catalyst potential and attractive valuation. Buy rating.
numbers boosted at Jefferies. Shares of BIIB now seen reaching $120. Estimates also upped, given higher Tysabri expectations. Buy rating.
estimates, target increased at Goldman. CNC estimates were raised through 2012. Company has a strong growth pipeline. Neutral rating and new $41 price target.
estimates, target adjusted at Citigroup. COV price target lowered to $64 on pressure on the peer group's multiple, according to Citigroup. Estimates increased through 2012. Buy rating.
estimates, target increased at Citigroup. Shares of DSW now seen reaching $62. Estimates also increased on growth in the leased division and owned units. Buy rating.
estimates, target raised at UBS. Shares of ERTS now seen reaching $29.50. Estimates also raised on strong pre-orders for important games. Buy rating.
(F - Get Report)
estimates lowered at UBS through 2011 to reflect less inventory restocking. Maintain $22 price target and Buy rating.
(GILD - Get Report)
estimates, target upped at Oppenheimer. GILD estimates were boosted through 2012. Company is seeing higher HIV sales. Outperform rating and new $46 price target.